Estados Unidos · Plataformas y datos · MarketBeat

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Publicado por MarketBeat · Estados Unidos hace 3 h

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

También te puede interesar

Anthropic's Revenue Surged to $16.3 Billion in the First Half of 2026, Up From $1.1 Billion a Year Ago

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Saudi Arabia intercepts Houthi missile as Trump threatens new strikes

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Why American Airlines (AAL) stock is down today

Hooters closes 35-year-old location after shutting 55 restaurants

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Compartir

También te puede interesar

Anthropic's Revenue Surged to $16.3 Billion in the First Half of 2026, Up From $1.1 Billion a Year Ago

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Saudi Arabia intercepts Houthi missile as Trump threatens new strikes

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Why American Airlines (AAL) stock is down today

Hooters closes 35-year-old location after shutting 55 restaurants